FDA Approval of Bosulif Adds to Toolkit of Treatment Options for Children With CML

The Food and Drug Administration (FDA) has approved Bosulif (bosutinib) for the treatment of children as young as 1 year old with newly diagnosed or resistant/intolerant to prior therapy chronic phase Philadelphia (Ph)-positive chronic myelogenous leukemia (CML).

Read more: https://www.curetoday.com/view/fda-approval-of-bosulif-adds-to-toolkit-of-treatment-options-for-children-with-cml